European Organisation for Research and Treatment of Cancer (EORTC) shared a post on LinkedIn:
“EORTC welcomes the EU Biotech Act as an important development for the European clinical research environment.
To maximise its impact, we propose targeted refinements to enhance clarity, reduce administrative burden, and better enable patient-centred clinical trials.
Read the full statement.”
Other articles from EORTC on OncoDaily.